Navigation Links
Flurizan's Effect in Delaying Progression From Mild Cognitive Impairment to Alzheimer's Disease is Superior to That of Aricept
Date:2/5/2008

Following its Launch in 2010, Myriad Genetics' Flurizan Will Earn a 23% Patient Share in the United States, According to a New Report from Decision

Resources

WALTHAM, Mass., Feb. 5 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a drug's effect on delaying the progression from mild cognitive impairment to Alzheimer's disease is the attribute that most influences neurologists' prescribing decisions in the treatment of mild cognitive impairment. Clinical trial data and expert opinion shows that Myriad Genetics' Flurizan has advantages in this attribute over Eisai/Pfizer's Aricept/Bracco's Memac, the current sales leader and gold standard therapy for mild cognitive impairment.

The new report entitled Mild Cognitive Impairment: An Off-Label Market with Significant Unmet Need and High Prevalence Carries Substantial Opportunity finds that, following its launch in 2010, Flurizan will replace Aricept as the gold standard for mild cognitive impairment. Surveyed U.S. neurologists indicate that they would prescribe Flurizan to 20% of their patients with mild cognitive impairment and the report forecasts that Flurizan will earn a 23% patient share in the U.S. market in 2016.

"Clinical trial data suggests that Flurizan has disease-modifying properties, an asset that interviewed experts expect will make the drug more effective at delaying the onset of Alzheimer's disease than currently available drugs," said Bethany Kiernan, Ph.D., analyst at Decision Resources. "Flurizan's safety and tolerability profile is also better than other emerging competitors, and this, along with its efficacy, will make it the gold standard in the treatment of mild cognitive impairment in 2016."

About the Report

Mild Cognitive Impairment: An Off-Label Market with Significant Unmet Need and High Prevalence Carries Substantial Opportunity is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price-per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources, Inc. (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be

trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
2. DNA sensors found to be an effective artificial nose
3. Free White Paper Available for Clinical Laboratory Managers: Effectively Isolating Anaerobic Bacteria
4. Job-related stress: NIST demonstrates fatigue effects in silicon
5. MedImmune to Present RSV Surveillance and Cost-Effectiveness Data at American Academy of Pediatrics National Conference & Exhibition
6. InVitrias Animal Free Lacromin(TM) Provides a Cost-Effective Improvement Over Transferrin
7. ProMed Alliance International Inc. Corporate Name and Trading Symbol Expected to Change Effective Tomorrow
8. American and European Parkinsons Sufferers Find Chinese Stem Cell Treatment Effective, Proving Western Debates Moot
9. New nanoparticle vaccine is more effective but less expensive
10. Panel to Discuss the Far-Ranging Effects and Consequences of Heart Disease, Which is the Leading Killer in Both Men and Women in the United States
11. Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... 24, 2017 , ... Chef Jodi Abel has returned from her three-week ... cities, she gained a number of delicious recipes and new techniques to share with ... Africa’s Western Cape province. It is internationally renowned for its incredible wine farms, ...
(Date:2/24/2017)... -- China Cord Blood Corporation (NYSE: CO ... cord blood collection, laboratory testing, hematopoietic stem cell processing ... financial results for the third quarter and first nine ... Third Quarter of Fiscal 2017 Highlights ... 2017 increased by 18.6% to RMB200.9 million ($28.9 million). ...
(Date:2/23/2017)... YORK , Feb. 23, 2017 ... digital health company, and Digital Noema Telehealth ... remote patient monitoring, announce they are partnering to ... DN Telehealth maximizes collaboration compatibility for its ... beyond a physical clinical setting to include fully ...
(Date:2/23/2017)... it seems everyone has a chance to express their personalities. ... and dynamic community unlike any other. The businesses that succeed ... With their newest salon in Dunwoody ... that tradition with a unique, fresh approach to head lice ... newest of 13 nationwide locations, each of them well-situated in ...
Breaking Biology Technology:
(Date:2/16/2017)... , Feb. 16, 2017  Genos, a ... announced that it has received Laboratory Accreditation from ... Accreditation is presented to laboratories that meet stringent ... demonstrate scientifically rigorous processes. "Genos is ... in laboratory practices. We,re honored to be receiving ...
(Date:2/10/2017)... -- Research and Markets has announced the ... Scientific and Commercial Aspects" to their offering. ... Biomarkers play ... therapy for selection of treatment as well for monitoring the ... disease in modern medicine. Biochip/microarray technologies and next generation sequencing ...
(Date:2/8/2017)... 7, 2017 Report Highlights ... The global synthetic-biology market reached ... by 2021, growing at a compound annual growth rate (CAGR) ... of the global markets for synthetic biology. - Analyses of ... and projections of compound annual growth rates (CAGRs) through 2021. ...
Breaking Biology News(10 mins):